rozlytrek
roche registration gmbh - entrectinib - cancer; carcinoma, non-small-cell lung - agenți antineoplazici - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.
treksta 25 mg
stada arzneimittel ag - germania - quetiapinum - compr. film. - 25mg - antipsihotice diazepine, oxazepine si tiazepine
treksta 100 mg
stada arzneimittel ag - germania - quetiapinum - compr. film. - 100mg - antipsihotice diazepine, oxazepine si tiazepine
treksta 200 mg
stada arzneimittel ag - germania - quetiapinum - compr. film. - 200mg - antipsihotice diazepine, oxazepine si tiazepine
treksta 300 mg
stada arzneimittel ag - germania - quetiapinum - compr. film. - 300mg - antipsihotice diazepine, oxazepine si tiazepine
rozlytrek 100 mg
roche farma ag - germania - entrectinibum - caps. - 100mg - inhibitori de protein-kinaza
rozlytrek 200 mg
roche farma ag - germania - entrectinibum - caps. - 200mg - inhibitori de protein-kinaza
pemetrexed stada 25 mg/ml
stadapharm gmbh - germania - pemetrexedum - conc. pt. sol. perf. - 25mg/ml - antimetaboliti analogi ai acidului folic
pemetrexed alvogen 500 mg
synthon hispania sl - spania - pemetrexedum - pulb. pt. conc. pt. sol. perf. - 500mg - antimetaboliti analogi ai acidului folic
pemetrexed alvogen 1000 mg
synthon hispania sl - spania - pemetrexedum - pulb. pt. conc. pt. sol. perf. - 1000mg - antimetaboliti analogi ai acidului folic